07:00 , Jun 14, 1999 |  BC Week In Review  |  Company News

Algene drug discovery news

The company's shareholders approved a name change to SignalGene Inc. Upon approval from the Montreal and Toronto Stock Exchanges, the company's ticker will change to SGI. Algene Biotechnologies Corp. (ME:AGN.B), Montreal, Quebec   Business: Drug...
07:00 , Jun 1, 1999 |  BC Week In Review  |  Company News

Algene, Genset deal

AGN.B will exclusively license to GENSET Alzheimer's disease (AD) DNA collections and gene mapping results that AGN.B has compiled from a phenotyped collection of samples from AD patients within the Quebec founder population. AGN.B has...
07:00 , Apr 12, 1999 |  BC Week In Review  |  Company News

Algene, Myriad Genetics deal

As a result of AGN.B’s restructuring in March, the companies will cancel a proposed agreement under which MYGN was planning to fund genetic research at AGN.B in three undisclosed areas of interest for MYGN (see...
08:00 , Mar 8, 1999 |  BC Week In Review  |  Company News

Algene, McGill University, Universite Laval deal

AGN acquired exclusive rights to intellectual property covering several disease-associated genes from the two universities in exchange for 14 million AGN shares. AGN received rights from McGill University to a pending U.S. patent covering the...
08:00 , Mar 8, 1999 |  BC Week In Review  |  Company News

Algene management update

(Deal, B2; financing, B13) Algene Biotechnologies Corp. (ME:AGN.B), Montreal, Quebec   Business: Drug discovery   Hired: Michael Dennis as president, CEO and chairman, formerly president of BioSignal Inc., replacing Denis Gauvreau; Lucie St-Georges as VP...
08:00 , Mar 8, 1999 |  BC Week In Review  |  Company News

Algene board of directors update

Algene Biotechnologies Corp. (ME:AGN.B), Montreal, Quebec   Business: Neurological   Appointed: Bernard Coupal, president of Gestion T2C2/BIO Inc.; and Francois Rousseau, associate professor in the medical biology department at the Universite Laval  ...
08:00 , Mar 1, 1999 |  BioCentury  |  Tools & Techniques

Founder population studies

The identification of disease-associated genes through the use of human genetic studies is difficult due to the often limited availability of suitable affected families, DNA samples and variability in physician diagnosis associated with such studies....
08:00 , Jan 25, 1999 |  BC Week In Review  |  Company News

Algene, Myriad Genetics deal

The companies agreed in principle that MYGN will fund genetic research at AGN.B in three undisclosed areas of interest for MYGN. MYGN will receive worldwide exclusive rights to the resulting compounds and AGN.B will be...
08:00 , Dec 7, 1998 |  BC Week In Review  |  Company News

Algene deal

AGN.B signed a letter of intent with an undisclosed biotechnology company for research into Alzheimer's disease. Under the terms of proposed agreement, AGN.B would obtain an initial one year research contract financed by its partner...
07:00 , Sep 14, 1998 |  BC Week In Review  |  Company News

Algene neurological news

AGN.B will lower its monthly expenditures from those in the first half of 1998 by one-third to about $236,000, and will reduce its employees from 55 to 43. The company said it will focus on...